ANNOUNCEMENT: Cambium’s Elate Ocular™ Biologic Topical Eye Drop in Clinical Study
A study titled “A Randomized Multicenter Double-Masked Placebo-Controlled Parallel Phase 1/2 Study to Determine the Safety and Exploratory Efficacy of Topical Fibrinogen-Depleted Human Platelet Lysate in Patients with Dry Eye Secondary to Graft vs. Host Disease” is underway at several U.S. clinical sites. GvHD dry eye is, as is dry eye in general, a chronic disease with no cure. Also called ocular graft vs. host disease, oGvHD is typically a severe form of dry eye with debilitating symptoms. oGvHD is triggered by a bone marrow transplant. As a result, oGvHD often impacts a patient’s quality of life. No FDA approved therapy exists today for oGvHD. Cambium’s study, is evaluating a standardized platelet-derived therapeutic for oGvHD. Study completion is targeted for later this year. Elate Ocular™’s biologic drug under study evaluation is Aurarix™ (fibrinogen-depleted human platelet lysate, or FD hPL), Cambium’s novel processed platelets.